4DMedical Limited announced the creation of a comprehensive cardiothoracic image analysis portfolio with the acquisition of Imbio.
Imbio is a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio’s regulatory cleared solutions transform the way patients are discovered, diagnosed and treated. It was a portfolio company of Invenshure, a biotechnology organization based in Minneapolis, Minnesota.
4DMedical Limited is a global medical technology company that has created a step change in the capacity to understand the lung function of patients with respiratory diseases. Through its flagship patented XV Technology®, 4DMedical enables physicians to understand lung airflow and identify respiratory deficiencies earlier.
According to the press release, Imbio compliments 4DMedical’s lung imaging technologies by providing quantitative and personalized imaging analysis for patients with acute and chronic diseases. The financial terms were not disclosed.
According to data captured in the LevinPro HC database, this transaction marks the 121st Laboratories, MRI and Dialysis acquisition of the year, and the sixth in the MRI specialty.
